Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec. The milestone reached was on the transition of an oncology programme into lead optimisation.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: "This is the eleventh milestone achieved as part of this alliance with Boehringer Ingelheim and the second against an oncology target. We continue to enjoy a very rich scientific partnership with Boehringer Ingelheim and look forward to continued success through our joint project teams in the coming years".
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.